Rise and shine, another busy day is on the way. We can tell because our short person is hunched over a laptop for another round of learning and our official mascot is bounding about the grounds while barking at critters. As for us, we are rifling through our fast-growing to-do list and brewing cups of stimulation. Our choice today is maple bourbon. Yes, this is a real flavor. Feel free to join us. Or grab a bottle of water, if you prefer. Meanwhile, here are some tidbits. We hope your day goes well, and do stay safe — wear a mask. …

Merck (MRK) will help Johnson & Johnson (JNJ) make its single-shot Covid-19 vaccine, an unusual pact between competitors that could boost the supply of the newly authorized shot, The Washington Post reports. Biden administration officials began searching for additional manufacturing capacity after they realized that J&J had fallen behind in vaccine production and sought to broker a deal with Merck, which had failed to develop its own coronavirus vaccine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]